Presentations & Publications

American Society of Cell and Gene Therapy, 2026

A Nutrient-Regulated GIP/GLP-1 AAV Gene Therapy to Durably Treat Obesity

Slomovic et al., presented at ASGCT 2026

Digestive Disease Week, 2026

Duodenal Mucosal Resurfacing Stabilizes Weight Loss and Glycemic Control After Glucagon-Like Peptide-1 Receptor Agonist Withdrawal: REVEAL-1 – A Prospective Multicenter Open-Label Study

Singh et al., presented at DDW 2026

Digestive Disease Week, 2026

Pancreas-targeted dual GIP/GLP-1 gene therapy reduces body weight and hepatic steatosis in a murine model of diet-induced obesity

Fitzpatrick et al., presented at DDW 2026

Digestive Disease Week, 2026

Endoscopic Duodenal Mucosal Resurfacing for Post-GLP-1 Weight Maintenance: 6-Month Randomized, Sham-Controlled Results from the REMAIN-1 Midpoint Cohort Study

Sullivan presented at DDW 2026

Meeting on the Mesa, 2025

Rejuva: Beta Cell-Targeted “Smart GLP-1” AAV Gene Therapy

Rajagopalan et al., presented at Meeting on the Mesa, Mesa, Arizona, October 7, 2025

View Presentation

Obesity Week 2025

Duodenal Mucosal Resurfacing Stabilizes Weight Loss After Glucagon-Like Peptide 1 Receptor Agonist Withdrawal

Singh, et al., presented at Obesity Week 2025

View Presentation

ADA, 2025

Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat Fed Mice

Kieffer, et al., presented at the American Diabetes Association’s 85th Scientific Sessions

View Presentation

American Society of Cell and Gene Therapy 2025

Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model

Fitzpatrick, et al., presented at the American Society of Cell and Gene Therapy (ASGCT) 2025

View Presentation

Digestive Disease Week, 2025

Feasibility and Safety of Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in a Porcine Model

Thompson et al., presented at Digestive Disease Week (DDW) 2025

View Presentation